Top Markets
Coin of the day
American Oriental Bioengineering, Inc. American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc.

AOBI
Rang in Aktien #42790
American Oriental Bioengineering, Inc. (AOBI), headquartered in Beijing, China,... American Oriental Bioengineering, Inc. (AOBI), headquartered in Beijing, China, focuses its operations on the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical and healthcare products. The company's core pharmaceutical offerings include a range of prescription medications. Among these are the Shuanghuanglian Lyophilized Injection Powder (SHL brand), prescribed to treat flu symptoms such as elevated fever, coughs, and sore throats, as well as to address upper respiratory tract infections, mild pneumonia, bronchitis, and tonsillitis. Another significant prescription product is the Cease Enuresis Soft Gel (CE Gel brand), formulated to alleviate bedwetting. AOBI's portfolio also extends to various over-the-counter (OTC) pharmaceutical solutions. These feature the Cease Enuresis Patch for managing bedwetting and urinary incontinence; Jinji Capsule, used for conditions like endometritis, annexitis, and pelvic inflammations; Jinji Yimucao, designed to relieve premenstrual syndrome (PMS) and other related menstrual and menopausal discomforts; and Boke Nasal Spray, which offers relief for sinus congestion associated with the common cold, nasal stuffiness, chronic rhinitis, allergic rhinitis, and nasosinusitis. Furthermore, the company develops and markets a selection of nutraceutical products, notably including soybean peptide-based items available as beverages, tablets, powders, and instant coffee. Beyond its manufacturing activities, AOBI is also involved in the wholesale and retail distribution of both its pharmaceutical and nutraceutical goods. The company's products are sold across the People's Republic of China through both direct channels and a network of distributors, reaching hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical retailers, and various other retail outlets.
Aktienkurs
$0.0012
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$88.00
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
140.00%
Land
CN
Handel American Oriental Bioengineering, Inc. (AOBI)

Kategorie

Gewinn für American Oriental Bioengineering, Inc. (AOBI)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von American Oriental Bioengineering, Inc. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von American Oriental Bioengineering, Inc. von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
$5.27B -
US
$1.95B -
NL
- -
CH
$3.01B -
BE
- -
KR